Next Generation Rat Models of ER+ Breast Cancer

下一代 ER 乳腺癌大鼠模型

基本信息

  • 批准号:
    10591512
  • 负责人:
  • 金额:
    $ 58.52万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-03-14 至 2027-02-28
  • 项目状态:
    未结题

项目摘要

Title: Next Generation Rat Models of ER+ Breast Cancer Abstract: Despite the prevalence of estrogen receptor-positive (ER+) breast cancer (BCa), there are no mammalian models that are immunocompetent and metastasize spontaneously to clinically relevant organs such as bones. ER+ BCs comprise ~70% of BCa cases and are treated with surgical resection and adjuvant endocrine therapies. Although the 5-year survival rate is high, risk of metastatic recurrence persists for dec- ades, and 20-40% of ER+ BCa patients eventually succumb to metastatic disease, most often in bones. Our limited knowledge of ER+ BCa has been largely derived from oversimplified cell line models and in vitro experiments. Our available xenograft models exclude the critical immune component while genetically engineered mouse models (GEMMs) rarely stably maintain ER expression and rely on ER signaling – and none metastasize to bone, the most frequent site. As a result, very little is known about the initial tumori- genesis process and bone metastasis of ER+ BCa, which greatly impedes our effort to develop new prevention strategies or adjuvant therapeutics that can block/treat ER+ BCa bone metastasis. We have developed a series of rat ER+ BCa models by intraductal injection of viruses to introduce genetic alterations. Our preliminary data demonstrated that these rat ER+ mammary tumors: 1) developed in immunocompetent hosts, 2) showed endocrine therapy sensitivity or resistance, and 3) readily formed ER+ metastases including in bone – all of which are key properties that are lacking in existing BCa models. Based on these, we hypothesize that rat-based intraductal injection models (RIIMs) of breast cancer faithfully recapitulate human ER+ BCa in terms of tumor initiation, metastasis, and therapeutic responses. We will pursue the following three aims: (1) To characterize early progression of ER+ BCa in RIIM models. (2) To characterize the metastatic behaviors of ER+ BCa in RIIM models. (3) To credential ER+ RIIM models in recapitulating therapeutic responses and resistance mechanisms of human ER+ BCa.
下一代ER+乳腺癌大鼠模型 翻译后摘要:尽管雌激素受体阳性(ER+)乳腺癌(BCa)的患病率,没有 具有免疫活性并自发转移至临床相关器官的哺乳动物模型 例如骨头。ER+ BCs占BCa病例的约70%,可通过手术切除和辅助治疗进行治疗 内分泌疗法虽然5年生存率很高,但转移复发的风险持续到12月。 20-40%的ER+ BCa患者最终死于转移性疾病,最常见于骨中。我们 ER+ BCa的有限知识主要来源于过度简化的细胞系模型和体外研究, 实验我们现有的异种移植模型排除了关键的免疫成分, 工程小鼠模型(GEMM)很少稳定地维持ER表达并依赖于ER信号传导, 没有转移到骨,最常见的部位。因此,对最初的肿瘤知之甚少- ER+ BCa的发生过程和骨转移,这极大地阻碍了我们开发新的预防措施的努力。 可以阻断/治疗ER+ BCa骨转移的策略或辅助疗法。我们已经开发出一种 通过导管内注射病毒以引入遗传改变的一系列大鼠ER+ BCa模型。我们 初步数据表明这些大鼠ER+乳腺肿瘤:1)在免疫活性宿主中发生, 2)表现出内分泌治疗敏感性或耐药性,3)易形成ER+转移,包括骨转移 - 所有这些都是现有BCa模型中缺乏的关键特性。基于这些,我们假设, 基于大鼠的乳腺癌导管内注射模型(RIIM)忠实地再现了人类ER+ BCa, 在肿瘤发生、转移和治疗反应方面。我们会致力达致以下三个目标:(1) 表征RIIM模型中ER+ BCa的早期进展。(2)为了表征转移行为, RIIM模型中的ER+ BCa。(3)验证ER+ RIIM模型在概括治疗反应和 人ER+ BCa的耐药机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Yi Li其他文献

Yi Li的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Yi Li', 18)}}的其他基金

Lactation on Breast Tumorigenesis
哺乳期对乳腺肿瘤发生的影响
  • 批准号:
    10668820
  • 财政年份:
    2023
  • 资助金额:
    $ 58.52万
  • 项目类别:
Mutating E-cadherin in rats to model lobular breast cancer
突变大鼠 E-钙粘蛋白以模拟小叶乳腺癌
  • 批准号:
    10830164
  • 财政年份:
    2022
  • 资助金额:
    $ 58.52万
  • 项目类别:
Next Generation Rat Models of ER+ Breast Cancer
下一代 ER 乳腺癌大鼠模型
  • 批准号:
    10464834
  • 财政年份:
    2022
  • 资助金额:
    $ 58.52万
  • 项目类别:
New Statistical Methods for Modelling Cancer Outcomes
癌症结果建模的新统计方法
  • 批准号:
    10542801
  • 财政年份:
    2021
  • 资助金额:
    $ 58.52万
  • 项目类别:
New Statistical Methods for Modelling Cancer Outcomes
癌症结果建模的新统计方法
  • 批准号:
    10317123
  • 财政年份:
    2021
  • 资助金额:
    $ 58.52万
  • 项目类别:
CSF Clearance in Sporadic Alzheimer's Disease
散发性阿尔茨海默病的脑脊液清除率
  • 批准号:
    10606516
  • 财政年份:
    2019
  • 资助金额:
    $ 58.52万
  • 项目类别:
CSF Clearance in Sporadic Alzheimer's Disease
散发性阿尔茨海默病的脑脊液清除率
  • 批准号:
    9981182
  • 财政年份:
    2019
  • 资助金额:
    $ 58.52万
  • 项目类别:
CSF Clearance in Sporadic Alzheimer's Disease
散发性阿尔茨海默病的脑脊液清除率
  • 批准号:
    9993210
  • 财政年份:
    2019
  • 资助金额:
    $ 58.52万
  • 项目类别:
CSF Clearance in Sporadic Alzheimer's Disease
散发性阿尔茨海默病的脑脊液清除率
  • 批准号:
    10390277
  • 财政年份:
    2019
  • 资助金额:
    $ 58.52万
  • 项目类别:
The Regulation of Gene Expression via Epigenetic Mechanisms during Onset of Obesity, Type 2 Diabetes
肥胖、2 型糖尿病发病期间通过表观遗传机制调节基因表达
  • 批准号:
    9270051
  • 财政年份:
    2016
  • 资助金额:
    $ 58.52万
  • 项目类别:

相似国自然基金

greenwashing behavior in China:Basedon an integrated view of reconfiguration of environmental authority and decoupling logic
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    万元
  • 项目类别:
    外国学者研究基金项目

相似海外基金

METABOLISM: accelerator Mass SpEctrometry to quanTify nanoplastics and decipher their fAte and Behavior in envirOnmentaL and bIological SysteMs
代谢:加速器质谱法可量化纳米塑料并破译其在环境和生物系统中的命运和行为
  • 批准号:
    EP/Y002733/1
  • 财政年份:
    2024
  • 资助金额:
    $ 58.52万
  • 项目类别:
    Research Grant
REU Site: Ecology, Evolution, and Behavior Field Research at Mountain Lake Biological Station
REU 站点:山湖生物站的生态、进化和行为领域研究
  • 批准号:
    2349462
  • 财政年份:
    2024
  • 资助金额:
    $ 58.52万
  • 项目类别:
    Standard Grant
BRITE Pivot: Growing Biological Methods to Improve Soil Behavior for Infrastructure Protection
BRITE 支点:不断发展生物方法来改善土壤行为以保护基础设施
  • 批准号:
    2227491
  • 财政年份:
    2023
  • 资助金额:
    $ 58.52万
  • 项目类别:
    Standard Grant
Biological Mechanisms of Suicidal Behavior among Sexual Minority Adolescents - Supplement
性少数青少年自杀行为的生物学机制 - 补充
  • 批准号:
    10823709
  • 财政年份:
    2023
  • 资助金额:
    $ 58.52万
  • 项目类别:
The role of biological interactions in the evolution of animal behavior
生物相互作用在动物行为进化中的作用
  • 批准号:
    RGPIN-2019-06689
  • 财政年份:
    2022
  • 资助金额:
    $ 58.52万
  • 项目类别:
    Discovery Grants Program - Individual
The virtual rodent: a platform to study the artificial and biological control of natural behavior
虚拟啮齿动物:研究自然行为的人工和生物控制的平台
  • 批准号:
    10540574
  • 财政年份:
    2022
  • 资助金额:
    $ 58.52万
  • 项目类别:
The Virtual Rodent: A Platform to Study the Artificial and Biological Control of Natural Behavior
虚拟啮齿动物:研究自然行为的人工和生物控制的平台
  • 批准号:
    10633144
  • 财政年份:
    2022
  • 资助金额:
    $ 58.52万
  • 项目类别:
Schooling through Vortex Streets; A Biological and Computational Approach to Understanding Collective Behavior in Wild Fish
通过涡街 (Vortex Street) 上学;
  • 批准号:
    2102891
  • 财政年份:
    2021
  • 资助金额:
    $ 58.52万
  • 项目类别:
    Continuing Grant
The role of biological interactions in the evolution of animal behavior
生物相互作用在动物行为进化中的作用
  • 批准号:
    RGPIN-2019-06689
  • 财政年份:
    2021
  • 资助金额:
    $ 58.52万
  • 项目类别:
    Discovery Grants Program - Individual
REU Site: Biological Basis of Social Behavior
REU 网站:社会行为的生物学基础
  • 批准号:
    1852338
  • 财政年份:
    2020
  • 资助金额:
    $ 58.52万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了